Table 3.

DSA

VariableEverolimus (n=476)MPA (n=477)
DSA at baseline
 Yes29 of 263 (11.0)37 of 292 (12.7)
  Anti-class I11 of 263 (4.2)11 of 292 (3.8)
  Anti-class II9 of 263 (3.4)12 of 292 (4.1)
  Both anti-class I and anti-class II10 of 263 (3.8)14 of 292 (4.8)
 No234 of 263 (89.0)255 of 292 (87.3)
 Missing213185
DSA at month 12
 Yes51 of 374 (13.6)47 of 339 (13.9)
  Anti-class I12 of 374 (3.2)16 of 339 (4.7)
  Anti-class II24 of 374 (6.4)24 of 339 (7.1)
  Both anti-class I and anti-class II15 of 374 (4.0)7 of 339 (2.1)
 No323 of 374 (86.4)292 of 339 (86.1)
 Missing102138
de novo DSA at month 12a
 Yes19 of 187 (10.2)25 of 184 (13.6)
  Anti-class I5 of 187 (2.7)8 of 184 (4.3)
  Anti-class II10 of 187 (5.3)14 of 184 (7.6)
 Both anti-class I and anti-class II4 of 187 (2.1)3 of 184 (1.6)
 No168 of 187 (89.8)159 of 184 (86.4)
  • a In patients without DSA at baseline in whom DSA were assessed at month 12.